undamentalytics Newsletter
Sign in

Opus Genetics, Inc. income statement

In fiscal 2025, Opus Genetics, Inc. reported revenue of $14.2m, up 29.1% on the year before, operating income of −$38.6m (a -271.9% margin) and net income of −$49.6m, or −$0.80 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue000003014019111410
Cost of revenue0————————————
Gross profit−0————————————
Research and development34123357151418273139
General and administrative36435238712182222
Operating income−6−10−16−7−8−4−20−2318−11−62−39−51
Interest expense—————17000000
Income before tax—————−6−25−5718−10−58−50−108
Income tax0000000000000
Net income−3−14−11−6−9−6−25−5718−10−58−50−108
Diluted EPS−$0.05−$0.18−$1.20−$0.60−$0.70−$2.17−$5.28−$3.82$0.87−$0.46−$2.15−$0.80−$1.23
Diluted shares (average)————1m3m5m15m21m22m27m62m87m
EBITDA−6−10−16−7−8−4−20−2318−11−62−39−51

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CRBU vs IRDIRD vs RLAYHYFT vs IRD

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Opus Genetics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Opus Genetics, Inc.